- Home
- CLYM vs TCRX Comparison
CLYM vs TCRX Comparison
Compare CLYM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- TCRX
- Stock Information
- Founded
- CLYM 2018
- TCRX 2018
- Country
- CLYM United States
- TCRX United States
- Employees
- CLYM N/A
- TCRX N/A
- Industry
- CLYM
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- TCRX Health Care
- Exchange
- CLYM NYSE
- TCRX Nasdaq
- Market Cap
- CLYM 83.8M
- TCRX 82.1M
- IPO Year
- CLYM 2021
- TCRX 2021
- Fundamental
- Price
- CLYM $1.49
- TCRX $1.81
- Analyst Decision
- CLYM Buy
- TCRX Strong Buy
- Analyst Count
- CLYM 1
- TCRX 6
- Target Price
- CLYM $10.00
- TCRX $9.50
- AVG Volume (30 Days)
- CLYM 210.7K
- TCRX 319.7K
- Earning Date
- CLYM 08-13-2025
- TCRX 08-11-2025
- Dividend Yield
- CLYM N/A
- TCRX N/A
- EPS Growth
- CLYM N/A
- TCRX N/A
- EPS
- CLYM N/A
- TCRX N/A
- Revenue
- CLYM N/A
- TCRX $4,421,000.00
- Revenue This Year
- CLYM N/A
- TCRX $159.20
- Revenue Next Year
- CLYM N/A
- TCRX N/A
- P/E Ratio
- CLYM N/A
- TCRX N/A
- Revenue Growth
- CLYM N/A
- TCRX N/A
- 52 Week Low
- CLYM $1.05
- TCRX $1.02
- 52 Week High
- CLYM $8.87
- TCRX $7.31
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- TCRX 53.96
- Support Level
- CLYM N/A
- TCRX $1.76
- Resistance Level
- CLYM N/A
- TCRX $1.99
- Average True Range (ATR)
- CLYM 0.00
- TCRX 0.12
- MACD
- CLYM 0.00
- TCRX -0.01
- Stochastic Oscillator
- CLYM 0.00
- TCRX 22.92
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.